3don MSN
Diabetes drug and antihistamine could together repair multiple sclerosis damage, trial finds
A combination of metformin, a common diabetes drug, and clemastine, an antihistamine, can help repair myelin—the protective ...
Anthony Durkacz, Executive Co-Chairman of Quantum BioPharma added, “We are very excited about the potential of Lucid-MS as a first-in-class treatment for MS targeting demyelination. With these final ...
The company was expecting a decision from the FDA by Sept. 28 for its oral drug tolebrutinib, but an update to the drug’s ...
Combining the diabetes medication metformin and the antihistamine clemastine increased myelin repair in people with RRMS, ...
The FDA has extended the review period of the New Drug Application for tolebrutinib for the treatment of non-relapsing, secondary progressive MS and to slow disability accumulation independent of ...
MedPage Today on MSN
Novel Drug Shows Hints of Promise for Progressive MS
Vidofludimus calcium currently is being evaluated in relapsing MS in two phase III trials, ENSURE-1 and ENSURE-2. The phase ...
Those who prescribe larger amounts of MS drugs were more likely to have received payments, and those who got payments were ...
A California federal judge has determined that biotech company Biogen owes Roche's Genentech more than $88 million in patent ...
On Monday, the U.S. Food and Drug Administration (FDA) extended the review date for Sanofi SA’s (NASDAQ:SNY) new drug ...
Zacks Investment Research on MSN
FDA Extends Review Period of Sanofi's Multiple Sclerosis Drug Filing
Sanofi SNY announced that the FDA has extended the target action date for its new drug application (NDA) for tolebrutinib by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback